Fear of ‘Humanized’ Pigs Hinders Advances in Organ Transplantation

Research aimed at growing human organs inside pigs has encountered significant regulatory hurdles, primarily due to concerns about the ethical implications of creating “humanized” animals. While gene-edited pig kidneys are being successfully transplanted into patients, federally funded efforts to develop fully human organs in pigs remain stalled.

This regulatory impasse stems from a decision made by the National Institutes of Health (NIH) in 2015, which halted funding for projects that involved introducing human stem cells into animal embryos. The NIH’s rationale centered on fears that human cells could migrate to the brain of the animal, potentially altering its cognitive functions. Such concerns have led to a cautious approach toward xenotransplantation, where organs from one species are transplanted into another.

In October 2025, surgeons in New York performed a groundbreaking procedure by transplanting a genetically modified pig kidney into a living patient. This marked the first clinical trial of its kind, focusing on pig organs engineered to minimize immune rejection rather than those developed with human cells. Six patients are participating in the trial, which seeks to determine the safety and functionality of gene-edited pig organs in humans, according to Live Science.

The field of xenotransplantation is driven by a pressing need. In the United States, over 100,000 individuals are on organ transplant waiting lists, with thousands dying each year while awaiting a compatible donor. Researchers have explored cross-species organ solutions for decades, ranging from baboon hearts in the 1960s to modern pigs modified with precision gene-editing techniques like CRISPR.

Despite advancements, the immune response remains a significant barrier. Recipients of pig organs often require lifelong immunosuppressant medications to prevent rejection. A patient from New Hampshire, who received a pig kidney in January 2025, had to have the organ removed nine months later due to a decline in its function, highlighting the ongoing challenges in this area.

The initial excitement surrounding the possibility of using a patient’s own cells to grow organs in animals has diminished following the NIH’s suspension of funding. Researchers had envisioned a process whereby an animal’s ability to develop a specific organ could be disabled, allowing human stem cells to take over. This method promised to create patient-matched organs with a significantly reduced risk of rejection. Successful proof-of-concept studies had previously demonstrated the feasibility of growing a mouse pancreas inside a rat.

Ethical considerations, rather than technical limitations, have impeded this promising line of research. Regulators remain focused on the potential for human cells to influence an animal’s brain and moral status. Ethicists argue that this distinction is arbitrary, especially since pigs already contain human genes to facilitate organ transplants. The current regulatory framework tracks species rather than the cellular composition of the organisms involved.

Consequently, the medical community navigates a complex regulatory landscape. While the transplantation of pig organs into humans is widely accepted, the pursuit of developing human organs within pigs remains off-limits. This situation reflects a broader tension between scientific innovation and ethical concerns, underscoring the challenges that still lie ahead in the quest for viable organ transplantation solutions.